Health Care & Life Sciences » Pharmaceuticals | Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc. | Ownership

Companies that own Intellipharmaceutics International Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Armistice Capital LLC
8,600,000
19.75%
0
0.18%
06/30/2018
Argent Trust Co. (Tennessee)
59,693
0.14%
0
0%
06/30/2018
Boothbay Fund Management LLC
37,196
0.09%
37,196
0%
06/30/2018
Verity Asset Management, Inc.
30,000
0.07%
0
0.01%
06/30/2018
Vision2020 Wealth Management Corp.
29,462
0.07%
-831
0%
06/30/2018
Barclays Capital, Inc.
28,259
0.07%
15,760
0%
06/30/2018
Two Sigma Securities LLC
25,905
0.06%
25,905
0%
06/30/2018
UBS Securities LLC
23,394
0.05%
23,394
0%
06/30/2018
Morgan Stanley Canada Ltd.
21,300
0.05%
4,000
0%
06/30/2018
Medical Strategy GmbH
16,570
0.04%
0
0%
06/30/2017

About Intellipharmaceutics International

View Profile
Address
30 Worcester Road
Toronto Ontario M9W 5X2
Canada
Employees -
Website http://www.intellipharmaceutics.com
Updated 09/14/2018
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of existing and new pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The company was founded by Isa Odidi and Amina Odidi on October 22, 2009 and is headquartered in Toronto, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.